Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-25 @ 1:46 AM
NCT ID:
NCT05037994
Brief Summary:
The patients will be randomly allocated into two equal groups (each 20 patients) using sealed opaque numbered envelopes:
Control Group (C Group) : Patients receive continuous US suprascapular nerve block only.
Gabapentin Group (G Group) : Patients receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
Both groups compared as regard:
Visual Analogue Scale Range of passive and active movements Patients satisfaction complication related to block The total dose of diclofenac sodium
Study:
NCT05037994
Study Brief:
Protocol Section:
NCT05037994